Zevra Therapeutics, Inc. 1GDA.F Stock
Zevra Therapeutics, Inc. Price Chart
Zevra Therapeutics, Inc. 1GDA.F Financial and Trading Overview
Zevra Therapeutics, Inc. stock price | 4.3 EUR |
Previous Close | 5.3 EUR |
Open | 5.3 EUR |
Bid | 5.35 EUR x N/A |
Ask | 5.45 EUR x N/A |
Day's Range | 5.3 - 5.3 EUR |
52 Week Range | 3.81 - 6.68 EUR |
Volume | 625 EUR |
Avg. Volume | 20 EUR |
Market Cap | 180.65M EUR |
Beta (5Y Monthly) | 2.192253 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.21 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
1GDA.F Valuation Measures
Enterprise Value | 98.41M EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 19.275612 |
Price/Book (mrq) | 2.5154247 |
Enterprise Value/Revenue | 10.501 |
Enterprise Value/EBITDA | -2.816 |
Trading Information
Zevra Therapeutics, Inc. Stock Price History
Beta (5Y Monthly) | 2.192253 |
52-Week Change | 35.61% |
S&P500 52-Week Change | 20.43% |
52 Week High | 6.68 EUR |
52 Week Low | 3.81 EUR |
50-Day Moving Average | 4.84 EUR |
200-Day Moving Average | 5 EUR |
1GDA.F Share Statistics
Avg. Volume (3 month) | 20 EUR |
Avg. Daily Volume (10-Days) | 62 EUR |
Shares Outstanding | 33.88M |
Float | 30.59M |
Short Ratio | N/A |
% Held by Insiders | 11.12% |
% Held by Institutions | 17.84% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -383.13% |
Gross Margin | 95.09% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -19.32% |
Return on Equity (ttm) | -53.33% |
Income Statement
Revenue (ttm) | 9.37M EUR |
Revenue Per Share (ttm) | 0.27 EUR |
Quarterly Revenue Growth (yoy) | -27.40% |
Gross Profit (ttm) | 10.12M EUR |
EBITDA | -34949000 EUR |
Net Income Avi to Common (ttm) | -51446000 EUR |
Diluted EPS (ttm) | -1.47 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 95.28M EUR |
Total Cash Per Share (mrq) | 2.81 EUR |
Total Debt (mrq) | 14.13M EUR |
Total Debt/Equity (mrq) | 19.78 EUR |
Current Ratio (mrq) | 6.678 |
Book Value Per Share (mrq) | 2.107 |
Cash Flow Statement
Operating Cash Flow (ttm) | -19209000 EUR |
Levered Free Cash Flow (ttm) | -9963875 EUR |
Profile of Zevra Therapeutics, Inc.
Country | Germany |
State | FL |
City | Celebration |
Address | 1180 Celebration Boulevard |
ZIP | 34747 |
Phone | 321 939 3416 |
Website | https://zevra.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 32 |
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Q&A For Zevra Therapeutics, Inc. Stock
What is a current 1GDA.F stock price?
Zevra Therapeutics, Inc. 1GDA.F stock price today per share is 4.3 EUR.
How to purchase Zevra Therapeutics, Inc. stock?
You can buy 1GDA.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Zevra Therapeutics, Inc.?
The stock symbol or ticker of Zevra Therapeutics, Inc. is 1GDA.F.
Which industry does the Zevra Therapeutics, Inc. company belong to?
The Zevra Therapeutics, Inc. industry is Biotechnology.
How many shares does Zevra Therapeutics, Inc. have in circulation?
The max supply of Zevra Therapeutics, Inc. shares is 41.98M.
What is Zevra Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Zevra Therapeutics, Inc. PE Ratio is now.
What was Zevra Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Zevra Therapeutics, Inc. EPS is -1.21 EUR over the trailing 12 months.
Which sector does the Zevra Therapeutics, Inc. company belong to?
The Zevra Therapeutics, Inc. sector is Healthcare.